Monte Rosa Therapeutics
GLUE
10.17
+0.30
+3.04%
Monte Rosa Therapeutics
US · GLUE
#3350 by market cap
Listed 2021
10.17
+0.30
+3.04%
Live - 5344 symbols - heartbeat 305s ago
· 2026-10-08 09:06
Pre-market
10.02
-1.51%
After-hours
10.00
-1.67%
Overnight
10.14
-0.29%
- Market cap
- 867.64M
- P/E (TTM)i
- -5.81
- P/Bi
- 1.78
- EPSi
- -0.46
- Div yieldi
- 0.00%
- 52W posi
- 7%
Reader sentiment
Are you bullish or bearish on GLUE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.6 percentage points.
Institutional ownership
- Held by institutions
- 115.91% -2.56pp
- Institutions
- 228 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund48.02%
Hedge Fund39.67%
VC/PE Fund23.89%
Public Company2.64%
Private Company0.84%
Individual/Insider0.53%
Family Office/Trust0.37%
Government Pension Fund0.28%
Insurance Company0.18%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
10.39% · 8.86M sh
BlackRock
8.02% · 6.84M sh
New Enterprise Associates, Inc.
7.84% · 6.69M sh
Dimension Capital Partners, LLC
6.64% · 5.66M sh
TCG Crossover Management, LLC
5.42% · 4.62M sh
Vestal Point Capital, LP
5.39% · 4.60M sh
BVF Partners L.P.
5.23% · 4.46M sh
Baker Bros. Advisors LP
5.09% · 4.35M sh
Vanguard Capital Management, LLC
4.59% · 3.92M sh
State Street Global Advisors
4.37% · 3.73M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 12 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Markus Warmuth | Chief Executive Officer | 0.47% |
| Edmund Dunn | Vice President & Corporate Controller | 0.03% |
| Matthew Bowen | Corporate Controller & Principal Accounting Officer | 0.02% |
| Sharon Townson | Chief Technology Officer | 0.01% |
| Jennifer Champoux | Chief People & Operations Officer | 0.01% |
| Filip Janku | Chief Medical Officer | 0.00% |
| New Enterprise Associates, Inc. | -- | -- |
| Versant Venture Management, LLC | -- | -- |
| Christine Siu | Independent Director | -- |
| Andrew Schiff | Independent Chairperson | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-15 | Markus Warmuth | Chief Executive Officer | Open Market Disposition | -9,500 | $23.18 |
| 2026-07-14 | Jennifer Champoux | Chief People & Operations Officer | Derivative Exercise and Sale | -4,351 | $3.98–23.38 |
| 2026-07-05 | Sharon Townson | Chief Technology Officer | Derivative Exercise and Sale | -6,000 | $6.14–24.13 |
| 2026-06-30 | New Enterprise Associates, Inc. | -- | Other Acquisition | +15,000 | -- |
| 2026-06-30 | New Enterprise Associates, Inc. | -- | Other Disposition | -1,015,000 | -- |
| 2026-06-29 | Filip Janku | Chief Medical Officer | Derivative Exercise and Sale | -5,407 | $13.41–24.50 |
| 2026-06-28 | Anthony Manning | Director | Derivative Exercise and Sale | -10,000 | $4.16–23.11 |
| 2026-06-28 | Filip Janku | Chief Medical Officer | Derivative Exercise and Sale | -6,000 | $7.56–22.95 |
| 2026-06-23 | Filip Janku | Chief Medical Officer | Derivative Exercise and Sale | -36,000 | $7.56–21.42 |
| 2026-06-23 | Filip Janku | Chief Medical Officer | Intent to Sell (Form 144) | -30,000 | $20.71 |
| 2026-06-22 | Filip Janku | Chief Medical Officer | Automatic Disposition | -5,845 | $20.22 |
| 2026-06-22 | Sharon Townson | Chief Technology Officer | Derivative Exercise and Sale | -3,000 | $6.14–20.00 |
| 2026-06-22 | Jennifer Champoux | Chief People & Operations Officer | Derivative Exercise and Sale | -2,175 | $3.98–20.00 |
| 2026-06-16 | Sharon Townson | Chief Technology Officer | Derivative Exercise and Sale | -3,000 | $6.14–19.00 |
| 2026-06-16 | Jennifer Champoux | Chief People & Operations Officer | Derivative Exercise and Sale | -2,176 | $3.98–19.00 |
| 2026-06-10 | Christine Siu | Independent Director | Other Derivative Acquisition | +25,800 | $17.10 |
| 2026-06-10 | Andrew Schiff | Independent Chairperson | Other Derivative Acquisition | +25,800 | $17.10 |
| 2026-06-10 | Anthony Manning | Director | Other Derivative Acquisition | +25,800 | $17.10 |
| 2026-06-10 | Jan Skvarka | Independent Director | Other Derivative Acquisition | +25,800 | $17.10 |
| 2026-06-10 | Kimberly Blackwell | Independent Director & Member of Scientific Advisory Board | Other Derivative Acquisition | +25,800 | $17.10 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:06:36 · For reference only, not investment advice and not tailored to your situation.